Dihexa, 1401708-83-5
166 Inquiries
1401708-83-5
Reagent Grade
98%
SHANGHAI
cellmano
1g/vial
2029-12-31
Cagrilintide,SS-31, Elamipretide,Semaglutide,Tirzepatide,Retatrutide
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionECHEMI Editorial Reference
Dihexa is a synthetic peptide-based compound and angiotensin IV analog. As a research and pharmaceutical raw material, Dihexa is characterized by its defined molecular structure and peptide properties. It is primarily used for research, analytical testing, compound evaluation, and pharmaceutical development.
Basic Info-
Product Name:
Dihexa
Other Name:L-Isoleucinamide,N-(1-oxohexyl)-L-tyrosyl-N-(6-amino-6-oxohexyl)-;N-(1-Oxohexyl)-L-tyrosyl-N-(6-amino-6-oxohexyl)-L-isoleucinamide;Dihexa;N-Hexanoic-Tyr-Ile-(6)aminohexanoic amide
CAS No.:1401708-83-5
Molecular Formula:C27H44N4O5
InChIKeys:InChIKey=XEUVNVNAVKZSPT-JTJYXVOQSA-N
Molecular Weight:504.7
Exact Mass:504.66
Categories:
Characteristics-
Density:
1.111±0.06 g/cm3(Predicted)
Boiling Point:866.2±65.0 °C(Predicted)
Research-
Class:
Angiotensin IV-derived oligopeptide / HGF-c-Met potentiator
Status:Research compound — Not FDA approved
Mechanism:A synthetic, orally active, blood-brain-barrier-permeable oligopeptide (Hexanoyl-Tyr-Ile-Ahx-NH₂) derived from angiotensin IV. Dihexa binds hepatocyte growth factor (HGF) with high affinity (Kd = 65 pM) and allosterically potentiates HGF activity at its receptor c-Met, promoting dendritic spinogenesis and synaptogenesis. In preclinical models it was reported to be seven orders of magnitude more potent than BDNF at promoting synapse formation. Note: the foundational 2014 paper (McCoy AT, et al. Neurobiol Learn Mem. 2014) was retracted in 2025.
EC50 (HGF Binding KD):65 pM
Activity note:Dihexa is an HGF potentiator, not a direct receptor agonist. It does not activate c-Met alone but markedly augments HGF-induced c-Met activation at low nanomolar HGF concentrations. Functional synaptogenic activity was reported at 10⁻¹°–10⁻⁻ M (original data now subject to retraction).
Source:Original report: McCoy AT, et al. Neurobiol Learn Mem. 2014;115:112-120 (retracted 2025). Benoist CC, et al. J Pharmacol Exp Ther. 2014;351(3):628-637.
Clinical Development:
References-
PubChem:UNII:Literature:
Benoist CC, et al. J Pharmacol Exp Ther. 2014 — HGF/c-Met mechanism; McCoy AT, et al. Neurobiol Learn Mem. 2014 — Synaptogenesis data (Retracted 2025); Athira Pharma: Fosgonimeton (prodrug) pipeline status
Disclaimer:Dihexa is NOT FDA-approved or EMA-approved as a medicine. It is a research compound only. The foundational 2014 paper describing its synaptogenic potency was retracted in 2025. Its phosphate prodrug fosgonimeton failed a Phase 2/3 Alzheimer’s trial (LIFT-AD, 2024). This listing is for industrial and laboratory research use only. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
Cagrilintide,SS-31, Elamipretide,Semaglutide,Tirzepatide,Retatrutide
-
Location:
Room C608, Chiyuan venture park
-
Payment Terms:
TT against copy of documents,100% TT in advance
-
Average lead Time:
10
-
Total Annual Revenue:
$5 million-$10 million
-
Total Employees:
11-50
Cellmano Biotech Limited focus on researching and developing solid phase peptide synthesis methodology since 2011. Cellmano has 10 years experience in researching, developing and manufacturing peptides by solid peptide phase synthesis.
Cellmano not only provides cosmeceuticals peptide & generic peptides to the customers, but also offer peptide CMO service and custom peptides synthesis service depend on the requirement from the customers over the world. Cellmano has state-of-the-art labs armed with excellent instrument for synthesis, purify and analysis .Cellmao control the quality by checking the materials, supervising produce process and finally QC. Cellmano keep all the synthesis records , purify methods and analysis result for every batch peptide product with staff and time invovled in the archives. Synthesizing by classical solid phase mothed invented by Prof.Bruce Merrified and purifying by HPLC instrument, Cellmano supply the customers excellent peptide products with reasonable price ,while maintain high quality, to help the customers to cut down their cost and shorten the time . Cellmano is trying her best to complement the inventory for more than 2000 popular peptide products, to make sure the customers can get what they need in one week from Cellmano’s inventory. Also to saitisfy diverse request from different customers for different projects, Cellmano provide custom synthesis for peptides from mgs to kgs with the purity from crude to 98% .
-
-
Inquiry History166 Inquiries
Country Product Purchase Quantity Date Posted 
Canada
Dihexa lyophilized 1401708-83-5
1 Aug 23, 2026
Canada
Dihexa 1401708-83-5
1 G Mar 8, 2026 
Bulgaria
Customized peptides high purity Dihexa with fast shipping door to door CAS 1401708-83-5
10 G May 27, 2025 
United States
Dihexa
500 G Aug 19, 2026
United States
Dihexa
25 G Jan 26, 2025 
Russia
DIHEXA
50.00 G Aug 14, 2024
Canada
Dihexa
130 Aug 12, 2026 
Brazil
dihexa
90 MG Aug 4, 2026
United States
Dihexa raw powder
10 G Jul 26, 2026 
Singapore
Dihexa
10 PCS Jul 15, 2026
United States
Dihexa
1 G Jul 11, 2026 
Sweden
Dihexa
10 PCS Jul 8, 2026 
Australia
Dihexa
1 MT Jul 2, 2026
United States
Dihexa
10 G Jun 14, 2026 
Germany
Dihexa
1 G May 25, 2026 
Thailand
Dihexa
1 G May 12, 2026
United States
Dihexa
100 G May 4, 2026 
Italy
simona migliori
10 MT Apr 23, 2026
United States
Dihexa
1 G Apr 22, 2026 
Ecuador
DIHEXA
10 PCS Apr 19, 2026 Post an enquiry for this product